Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histological or cytological diagnosis of SCLC~* Limited disease (LD) or Extensive disease (ED) at time of study entry~* Recurrent or progressive SCLC ≥ 90 days of duration of response for firstline therapy~* Measurable disease defined by RECIST criteria~* ECOG Performance Status of 0, 1, or 2~* Life expectancy ≥ 3 months~* Adequate bone marrow, Renal, Hepatic reserve:~absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/mm3 platelet count ≥ 100,000 cells/ mm3 hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 mm3 Alanine aminotransferase (ALT) and aspartate aminotransferase(AST) ≤ 2.0 X ULN Alkaline Phosphatase (ALP) ≤ 2.0 X ULN Serum creatinine ≤ 1.5mg/dL or calculated creatinine clearance \> 60mL/min~- Signed a written informed consent~Exclusion Criteria:~* Active infection~* Symptomatic brain lesion~* Any other type of cancer during the previous 5 years~* Severe concurrent diseases~* Prior anticancer therapy within 4 weeks before enroll~* Active pregnancy test and Pregnant or nursing women~* Participation in any investigational drug study within 28 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belotecan (Type: EXPERIMENTAL): Camtobell Injection
- Topotecan (Type: ACTIVE_COMPARATOR): Hycamtin Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).